Drugs / EP31670
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05488548 | Dec 2022 → May 2025 overdue | castration-resistant prostate carcinoma, chronic myelomonocytic leukemia, myelofibrosis, nut midline carcinoma | Epigenetix, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EP31670 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05488548 ↗ |
| Known as | NEO2734 | “EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor.” NCT05488548 ↗ |
| Action | Inhibit | “EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor.” NCT05488548 ↗ |
| Route | Oral | “EP31670 administered orally in patients with castration-resistant prostate cancer, NUT midline carcinoma and other targeted advanced solid tumors as well as chronic...” NCT05488548 ↗ |